logo
T1 CELL SIGNALLING AND PHENOTYPIC CHANGES IN CHRONIC HYPOXIC PULMONARY ADVENTITIAL FIBROBLASTS: POSITIVE EFFECTS OF FLUVASTASTIN ARE NOT SEEN WITH ESTABLISHED PULMONARY HYPERTENSION AGENTS
T2 IL-33 IS SUFFICIENT TO INDUCE EOSINOPHILIC AIRWAY INFLAMMATION, AND EXACERBATES ESTABLISHED INFLAMMATION, THROUGH INCREASED ST2 DEPENDENT LOCAL TH2 CYTOKINE AND CHEMOKINE PRODUCTION
T3 TOWARDS TARGETED TREATMENT FOR α 1 -ANTITRYPSIN DEFICIENCY: RATIONALLY SELECTED SMALL MOLECULES ABOLISH THE POLYMERISATION OF Z α 1 -ANTITRYPSIN IN VITRO AND IN A LIVER CELL MODEL OF DISEASE
T4 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR LIGATION DIFFERENTIALLY REGULATES PRIMARY HUMAN ALVEOLAR TYPE II CELL REPAIR RESPONSES AND IS ANTI-APOPTOTIC FOR SFASL BUT NOT 0.03% H 2 O 2 INDUCED CELL DEATH
T5 AIRWAY NEOVASCULARISATION BY AIRWAY SMOOTH MUSCLE IN ASTHMA: NEW CONDUITS TO INFLAMMATION AND REMODELLING
T6 REGULATION OF ID GENE EXPRESSION BY MAPK AND SMAD1/5 PATHWAYS IN PULMONARY ARTERY SMOOTH MUSCLE CELLS
S1 THE OUTCOME OF A COHORT OF TUBERCULIN POSITIVE, PREDOMINANTLY SOUTH ASIAN, NEW ENTRANTS AGED 16–34 TO THE UK: BLACKBURN 1989–2001
S2 THE EPIDEMIOLOGY AND TREATMENT OF ENVIRONMENTAL MYCOBACTERIA IN THE PORTSMOUTH AREA
S3 INCREASING ANTI-TUBERCULOSIS DRUG RESISTANCE IN THE UK
S4 A COMPARISON OF TUBERCULOSIS CASE RATES IN THE HOME-BORN WHITE POPULATIONS OF THE UK AND USA: AN INCREASING DISPARITY
S5 ACCURATE DATA COLLECTION: IMPACT ON TREATMENT OUTCOMES AT A RURAL TB PROJECT IN ZIMBABWE
S6 INCREASING TREND OF NON-TUBERCULOUS MYCOBACTERIA IN ENGLAND, WALES AND NORTHERN IRELAND 1995–2006: REAL OR ARTEFACT?
S7 THE EFFECT OF MECHANICAL HEAT RECOVERY VENTILATION ON THE CONTROL OF ASTHMA: A RANDOMISED CONTROLLED TRIAL
S8 EXAMINING THE RELATION BETWEEN ASTHMA AND RHINITIS RESPONSE FOLLOWING OMALIZUMAB THERAPY
S9 EFFECT OF INHALED CORTICOSTEROIDS ON SMALL AIRWAY DYSFUNCTION IN MILD TO MODERATE PERSISTENT ASTHMATICS
S10 THE LONGITUDINAL CORRELATION BETWEEN FRACTIONAL EXHALED NITRIC OXIDE AND SPUTUM EOSINOPHIL COUNTS IN REFRACTORY ASTHMA
S11 A QUALITATIVE ANALYSIS OF HRCT SCANS IN DIFFICULT ASTHMA
S12 THE RELATIONSHIP BETWEEN GASTRO-OESOPHAGEAL REFLUX AND VOCAL CORD DYSFUNCTION IN A CLINICAL SETTING
S13 NON-INVASIVE VENTILATION IN PATIENTS WITH ACUTE CARDIOGENIC PULMONARY OEDEMA: THE 3CPO TRIAL (A MULTICENTRE RANDOMISED CONTROLLED TRIAL)
S14 SHORT- AND LONG-TERM MORTALITY FOLLOWING NON-INVASIVE VENTILATORY SUPPORT FOR ACUTE TYPE II RESPIRATORY FAILURE
S15 PREDICTORS OF A SUCCESSFUL OUTCOME IN NON-INVASIVE VENTILATION FOR ACUTE HYPERCAPNIC RESPIRATORY FAILURE: A PROSPECTIVE OBSERVATIONAL STUDY
S16 NON-INVASIVE VENTILATION IN MOTOR NEURON DISEASE: AN AUDIT OF CURRENT PRACTICE
S17 LONG-TERM OUTCOME OF VENTILATORY SUPPORT IN PATIENTS WITH RESPIRATORY FAILURE DUE TO DUCHENNE MUSCULAR DYSTROPHY
S18 PROSPECTIVE STUDY OF INITIATION OF HOME MECHANICAL VENTILATION TO INVESTIGATE THE CHANGES IN PATIENT DEMOGRAPHICS OVER A TWO-YEAR PERIOD
S19 FOURIER TRANSFORM INFRARED SPECTROSCOPY MEASURING METABOLIC MARKERS IN SPUTUM IN PATIENTS WITH AND WITHOUT LUNG CANCER
S20 DEGRANULATION OF STROMAL MAST CELLS OF THE TRYPTASE-ONLY PHENOTYPE IS ASSOCIATED WITH IMPROVED PROGNOSIS IN NON-SMALL CELL LUNG CANCER
S21 PROTEOMIC ANALYSIS OF RESECTABLE NON-SMALL CELL LUNG CANCER: IMPACT OF SMOKING, HISTOLOGICAL TYPE AND STAGE OF DISEASE
S22 QUALITY OF RNA EXTRACTED FROM BIOPSIES OF NON-SMALL CELL LUNG CANCER COLLECTED USING DIFFERENT TECHNIQUES
S23 THE ASSOCIATION OF LUNG CANCER AND SINGLE NUCLEOTIDE POLYMORPHISMS IN CODON 178 AND THE FIRST INTRON OF THE DNA REPAIR GENE O6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE
S24 IMPORTANT FACTORS IN SMOKING CESSATION IN OLDER PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE VERSUS CRITICAL LIMB ISCHAEMIA
S25 SMOKING CESSATION ADVICE FOR HOSPITAL IN-PATIENTS: ROOM FOR IMPROVEMENT
S26 A QUESTIONNAIRE SURVEY ON SMOKING POLICY AND SMOKING CESSATION TOOLS IN UK SECONDARY SCHOOLS
S27 EARLY EXPERIENCE WITH VARENICLINE IN A HOSPITAL-BASED SMOKING CESSATION CLINIC
S28 ACHIEVING A SMOKE-FREE SITE IN A DISTRICT GENERAL HOSPITAL: A SURVEY OF PERCEPTIONS OF HEALTHCARE WORKERS
S29 ATTITUDES OF CURRENT AND EX-SMOKERS TO THE BANNING OF SMOKING IN PUBLIC AND ENCLOSED SPACES IN ENGLAND
S30 BOSENTAN FOR INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: A RANDOMISED, PLACEBO-CONTROLLED TRIAL—BENEFIT
S31 PULMONARY ARTERY OCCLUSION PRESSURE ANALYSIS IN CHRONIC THROMBOEMBOLIC AND IDIOPATHIC PULMONARY HYPERTENSION
S32 A RANDOMISED CONTROLLED TRIAL TO INVESTIGATE THE EFFECTS OF A PHYSIOTHERAPIST-LED REHABILITATION PROGRAMME ON EXERCISE CAPACITY AND QUALITY OF LIFE MEASURES IN PATIENTS WITH PULMONARY HYPERTENSION
S33 NON-INVASIVE ASSESSMENT OF PULMONARY BLOOD FLOW USING AN INERT GAS REBREATHING DEVICE IN PATIENTS WITH PULMONARY HYPERTENSION
S34 ISCHAEMIC STROKES AND PULMONARY ARTERIOVENOUS MALFORMATIONS (PAVMs): PAVM EMBOLISATION REDUCES STROKE RISK
S35 BRAIN-NATRIURETIC PEPTIDE CORRELATES TO ECHOCARDIOGRAPHIC INDICES OF RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH FIBROTIC LUNG DISEASE
S36 SUCCESSFUL IMPLEMENTATION OF A NEW ACUTE OXYGEN GUIDELINE USING A TARGET DRIVEN OXYGEN SATURATION SYSTEM (THE BASIS OF THE NEW BTS GUIDELINE) WITH OXYGEN CHAMPIONS AND DROP-IN TEACHING
S37 TRAINING OF GENERAL PRACTICE NURSES: ARE WE PREPARED FOR THE NATIONAL SERVICE FRAMEWORK FOR COPD?
S38 SELF-MANAGEMENT IN BRONCHIECTASIS. AN EXPLORATORY RANDOMISED CONTROLLED TRIAL OF A DISEASE SPECIFIC EXPERT PATIENT PROGRAMME COMPARED TO USUAL CARE IN PATIENTS WITH BRONCHIECTASIS
S39 A SURVEY OF SPECIALIST REGISTRAR KNOWLEDGE OF RADIATION DOSES FOR VARIOUS RESPIRATORY INVESTIGATIONS
S40 WHAT DO PATIENTS WANT TO KNOW ABOUT COPD?
S41 ASTHMA NURSE ADVISOR PROGRAMMES CAN IMPROVE CARE WITHIN A HEALTH COMMUNITY
S42 AN IN-DEPTH STUDY TO DESCRIBE AND UNDERSTAND THE HEALTH EXPERIENCE OF TEENAGERS WITH UNCONTROLLED SEVERE ASTHMA: EXPERIENCES OF MEDICATION AND CONCORDANCE WITH THERAPY
S43 WHAT ARE THE FACTORS THAT UNDERLIE PAEDIATRIC ASTHMA?
S44 ARE YOUNG CHILDREN PRESENTING WITH COUGH IN THE ABSENCE OF WHEEZE AT INCREASED RISK FOR ASTHMA IN LATER CHILDHOOD?
S45 DIETARY INTAKE OF FRUIT AND CHILDHOOD ASTHMA
S46 RESULTS OF NURSE-LED HOME VISITS FOR CHILDREN WITH DIFFICULT ASTHMA
S47 THE ROLE OF T CELL BASED INTERFERON-γ RELEASE ASSAYS IN THE EVALUATION OF PATIENTS WITH SUSPECTED ACTIVE TUBERCULOSIS
S48 RAPID IMMUNO-DIAGNOSIS OF ACTIVE EXTRAPULMONARY TUBERCULOSIS
S49 AN ECONOMIC EVALUATION OF THE USE OF INTERFERON γ RELEASE ASSAYS IN THE SCREENING OF CONTACTS AND NEW ENTRANTS FOR LATENT TB
S50 TB CONTACT SCREENING IN IMMUNOCOMPROMISED HIV POSITIVE PATIENTS: IS THERE A RELATION BETWEEN T-SPOT TB REACTIVITY AND EXPOSURE TO THE INDEX CASE IN OUTPATIENT CONTACTS?
S51 T-SPOT-TB REACTIVITY FOLLOWING CHEMOPROPHYLAXIS FOR LATENT TUBERCULOSIS IN HIV POSITIVE PATIENTS
S52 QUANTIFERON-TB OR QFT IN SARCOIDOSIS
S53 OXIDATIVE STRESS INCREASES TRANSFORMING GROWTH FACTOR-BETA EXPRESSION AND DRIVES EPITHELIAL TO MESENCHYMAL TRANSITION IN HUMAN LUNG EPITHELIAL CELLS
S54 BALF PROTEIN PERMEABILITY INDEX AND MATRIX METALLOPROTEINASES IN IDIOPATHIC PULMONARY FIBROSIS: A LINK BETWEEN ABERRANT VASCULAR PERMEABILITY AND PROGNOSIS?
S55 LYSOPHOSPHATIDIC ACID INDUCES αVβ6 INTEGRIN MEDIATED TRANSFORMING GROWTH FACTOR-BETA ACTIVATION VIA GαQ IN EPITHELIAL CELLS
S56 DIFFERENTIAL MODULATION OF LUNG FIBROBLAST AND ALVEOLAR EPITHELIAL CELL APOPTOSIS BY CYCLO-OXYGENASE (COX)-2 AND PROSTAGLANDIN E 2 IS AN IMPORTANT MECHANISM IN THE PATHOGENESIS OF IDIOPATHIC PULMONARY FIBROSIS
S57 SERUM BIOMARKERS IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY FIBROSIS: KL-6 CORRELATES WITH DISEASE SEVERITY
S58 INCREASED SYSTEMIC INFLAMMATORY CYTOKINES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
S59 SLEEP DISORDERED BREATHING, A CAUSATIVE FACTOR IN THE DEVELOPMENT OF SEVERE DIABETIC RETINOPATHY?
S60 SLEEP DISORDERED BREATHING IN PATIENTS WITH UNILATERAL PARALYSIS OR SEVERE WEAKNESS OF THE DIAPHRAGM
S61 SLEEP DISORDERED BREATHING AND LEFT VENTRICULAR EJECTION FRACTION IN PATIENTS WITH STABLE MODERATE HEART FAILURE, WHO ARE ON OPTIMAL MEDICAL TREATMENT
S62 ENDOTHELIAL FUNCTION IN PATIENTS WITH MILD–MODERATE OBSTRUCTIVE SLEEP APNOEA
S63 SLEEP APNOEA: A MARKER OF VISCERAL OBESITY?
S64 HYPOXIA DECREASES HDAC2 IN U937 CELLS AS A POSSIBLE MECHANISM FOR GLUCOCORTICOID RESISTANCE IN COPD
S65 SPUTUM INTERLEUKIN-5 IS ELEVATED IN COPD SUBJECTS WITH EOSINOPHILIC AIRWAY INFLAMMATION AND DECREASES IN RESPONSE TO TREATMENT WITH ORAL CORTICOSTEROIDS
S66 THEOPHYLLINE RESTORES CORTICOSTEROID SENSITIVITY IN COPD CELLS VIA AN INHIBITORY EFFECT ON PI3K SIGNALLING
S67 LIGANDS FOR TLR-3 AND TLR-4 INITIATE DISTINCT CYTOKINE CASCADES IN HUMAN LUNG PARENCHYMAL TISSUE
S68 THE CONTRIBUTION OF GROWTH RELATED ONCOGENE ALPHA TO CHEMOTAXIS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ALPHA 1 ANTITRYPSIN DEFICIENCY
S69 VARIATION IN THE SURFACTANT PROTEIN B GENE IS ASSOCIATED WITH DEVELOPMENT OF EMPHYSEMA IN ALPHA 1 ANTI-TRYPSIN DEFICIENCY
S70 UK CF GENE THERAPY CONSORTIUM TRACKING STUDY: CHANGE IN SPUTUM PROPERTIES IN RESPONSE TO IV ANTIBIOTICS
S71 UK CF GENE THERAPY CONSORTIUM TRACKING STUDY: RESPONSE OF CLINICALLY AVAILABLE ASSAYS TO INTRAVENOUS ANTIBIOTICS
S72 COMPUTED TOMOGRAPHY IN INFECTIVE EXACERBATIONS IN CYSTIC FIBROSIS: SERIAL CHANGE AND OBSERVER AGREEMENT
S73 FUNCTIONAL AND STRUCTURAL CHANGES IN THE CYSTIC FIBROSIS LUNG FOLLOWING ANTIBIOTIC TREATMENT FOR EXACERBATION
S74 A CASE CONTROL STUDY OF ACUTE RENAL FAILURE IN CYSTIC FIBROSIS PATIENTS IN THE UK
S75 DO MICRONUTRIENTS USED AS SUPPLEMENTATION TO STANDARD TREATMENT SPEED RESOLUTION OF TUBERCULOSIS?
S76 OUTCOMES OF A TRIPLE THERAPY REGIMEN FOR NON-TUBERCULOUS MYCOBACTERIAL PULMONARY INFECTION
S77 IS THE WORLD HEALTH ORGANIZATION REGIMEN OF THRICE WEEKLY CATEGORY 1 (NEW SPUTUM SMEAR POSITIVE PATIENTS) TREATMENT SUFFICIENT FOR PATIENTS WHO HAVE A HIGH DENSITY OF ACID-FAST BACILLI IN THE SPUTUM?
S78 ARE ALL PATIENTS STARTING ETHAMBUTOL THERAPY RECEIVING ADEQUATE OPTIC NERVE FUNCTION SCREENING?
S79 BARRIERS TO INITIATING ANTIRETROVIRAL THERAPY IN HIV INFECTED PATIENTS WITH TUBERCULOSIS CO-INFECTION
S80 THE TREATMENT OF ISONIAZID RESISTANT TUBERCULOSIS WITH PREDOMINANTLY A 9 MONTH REGIMEN (2RZE/7RE)
S81 PRE-OPERATIVE CHEMOTHERAPY IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER: THE MRC LU22/NVALT/EORTC 08012 MULTICENTRE RANDOMISED TRIAL
S82 TWENTY-EIGHT DAYS FROM REFERRAL TO TREATMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER
S83 ANALYSIS OF A LUNG CANCER COHORT FOR VARIATION IN SURVIVAL OVER A 7 YEAR PERIOD
S84 SURVIVAL FOR PATIENTS WITH LUNG CANCER: THE IMPORTANCE OF PATIENTS WITH NO HISTOLOGICAL DIAGNOSIS
S85 NO IMPROVEMENT IN SURVIVAL FOR NON-SMALL CELL LUNG CANCER BETWEEN 1999 AND 2007: THE EXPERIENCE OF AN INNER LONDON TEACHING HOSPITAL
S86 SURVIVAL IN 176 PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG CANCER TREATED INITIALLY WITH CHEMOTHERAPY IN A DISTRICT GENERAL HOSPITAL
S87 THE ROLE OF ACTIVATOR PROTEIN-1 (AP-1) FAMILY MEMBERS IN THE INDUCTION OF INTERLEUKIN (IL)-8 BY CYCLIC MECHANICAL STRAIN IN LUNG EPITHELIAL CELLS
S88 LUNG-MARGINATED MONOCYTES PLAY A CENTRAL ROLE IN A TWO-HIT LPS-ZYMOSAN MODEL OF ACUTE LUNG INJURY IN MICE
S89 TRANSFORMING GROWTH FACTOR BETA (TGFβ) INDUCES CELLULAR SENESCENCE IN PRIMARY BRONCHIAL EPITHELIAL CELLS: A POSSIBLE ROLE IN AIRWAY REMODELLING
S90 ADAM33 IN LUNG DEVELOPMENT AND THE EFFECT OF MATERNAL ALLERGY
S91 STRUCTURE AND FUNCTIONAL ANALYSIS OF LIPOPOLYSACCHARIDE AND LIPID A OF BURKHOLDERIA MULTIVORANS STRAINS ISOLATED FROM CYSTIC FIBROSIS TRANSPLANT RECIPIENTS
S92 K5, A KAPOSI SARCOMA HERPESVIRUS GENE PRODUCT, TARGETS BONE MORPHOGENETIC PROTEIN RECEPTOR II FOR UBIQUITINATION AND ENDOSOMAL DEGRADATION
S93 CHARACTERISATION OF CHILDREN WITH DIFFICULT TO TREAT ASTHMA
S94 AIRWAY EPITHELIAL CELL MEDIATOR RELEASE IS ASSOCIATED WITH WHEEZING BUT NOT ATOPY IN CHILDREN
S95 DO LUNG FUNCTION TESTS AT 4–6 YEARS OF AGE IN SEVERE PRESCHOOL WHEEZERS CORRELATE WITH ENDOBRONCHIAL BIOPSY IN EARLY PRESCHOOL YEARS?
S96 EVIDENCE OF PERSISTENT SMALL AIRWAYS DISEASE MEASURED BY LUNG CLEARANCE INDEX IN WELL-CONTROLLED ASTHMATIC CHILDREN WITH NORMAL FEV 1
S97 CAN DAILY EXHALED NITRIC OXIDE MEASUREMENTS PREDICT A CLINICAL RESPONSE TO SYSTEMIC CORTICOSTEROIDS IN CHILDREN WITH DIFFICULT ASTHMA?
S98 IMPACT OF FDG-PET SCAN ON THE PREVALENCE OF BENIGN LESIONS AT THORACOTOMY
S99 DOES THE USE OF PREOPERATIVE CT-PET IMPROVE THE SURGICAL MANAGEMENT OF THE SOLITARY PULMONARY NODULE?
S100 IS SURGERY CONTRAINDICATED FOR PATIENTS WITH SMALL CELL LUNG CANCER AND CLINICAL N2 DISEASE?
S101 IMPLICATIONS OF ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION OF MEDIASTINAL LYMPH NODES FOR STAGING LUNG CANCER: A COST AND TIME-TO-TREATMENT PROJECTED ANALYSIS
S102 ENDOBRONCHIAL ULTRASOUND: A COMPARATIVE STUDY BETWEEN CONVENTIONAL TBNA AND EBUS-GUIDED TBNA
S103 THE USE OF THE DIODE LASER IN THERAPEUTIC BRONCHOSCOPY: AN INTEGRAL PART OF MODERN RESPIRATORY PRACTICE
S104 PHYSICIAN AND PATIENT PERCEPTION OF TOLERANCE TO FIBREOPTIC BRONCHOSCOPY
S105 CT-GUIDED LUNG BIOPSY: 150 CASE REVIEW
S106 INTRODUCING LIQUID BASED CYTOLOGY INTO ROUTINE BRONCHOSCOPY FOR PATIENTS WITH SUSPECTED LUNG CANCER
S107 DIAGNOSTIC VALUE AND RISKS OF TRANSBRONCHIAL LUNG BIOPSIES
S108 RANDOMISED CONTROLLED TRIAL OF THE EFFECT OF STANDARD AND DETAILED CONSENT FORMS FOR BRONCHOSCOPY ON PERI-PROCEDURE ANXIETY AND SATISFACTION
S109 SIX MINUTE WALK DESATURATION AND MAXIMAL EXERCISE TEST PARAMETERS: RELATION IN PATIENTS WITH FIBROSING LUNG DISEASE
S110 LUNG TRANSPLANTATION FOR IDIOPATHIC PULMONARY FIBROSIS: RECIPIENT CHARACTERISTICS AND SURVIVAL OUTCOMES IN A SINGLE CENTRE 1987–2007
S111 THE RISK OF ACUTE CORONARY SYNDROMES, CEREBROVASCULAR ACCIDENTS AND DEEP VEIN THROMBOSES IN PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS AND THE GENERAL POPULATION
S112 DOES BODY MASS INDEX INFLUENCE INFLAMMATION AND PLASMA LIPIDS IN PIGEON FANCIERS’ ALLERGIC ALVEOLITIS
S113 AMBULATORY OXYGEN IN IDIOPATHIC PULMONARY FIBROSIS: OF WHAT BENEFIT?
S114 SYSTEMIC SCLEROSIS-RELATED DIFFUSE PULMONARY FIBROSIS QUANTIFIED BY HIGH RESOLUTION COMPUTED TOMOGRAPHY: AUTOANTIBODY AND HLA ASSOCIATIONS
S115 EFFECT OF LONG-TERM ERYTHROMYCIN IN COPD TRIAL (ELECT): EXACERBATIONS AND INFLAMMATION
S116 ERDOSTEINE IN ASSOCIATION WITH AMOXICILLIN IMPROVES THE OUTCOME OF ACUTE EXACERBATIONS COMPARED TO AMOXICILLIN ALONE IN COPD PATIENTS
S117 COST-EFFECTIVENESS OF ERDOSTEINE IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
S118 FAST ONSET OF ANTIOXIDANT ACTIONS OF ERDOSTEINE AND ITS POTENTIAL USE FOR ACUTE TREATMENT OF COPD EXACERBATIONS
S119 INITIAL EXPERIENCE WITH AN EMPHYSEMA MULTIDISCIPLINARY MEETING FOR THE MANAGEMENT OF PATIENTS FOR LUNG VOLUME REDUCTION
S120 ACCURACY OF PLEURAL FLUID PH MEASUREMENT IS CRITICALLY INFLUENCED BY SAMPLE COLLECTION AND HANDLING
S121 A RANDOMISED PHASE III TRIAL OF ACTIVE SYMPTOM CONTROL WITH OR WITHOUT CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA. THE MEDICAL RESEARCH COUNCIL/BRITISH THORACIC SOCIETY MS01 TRIAL
S122 THE RELATION BETWEEN CHEST TUBE BORE, CLINICAL OUTCOME AND TUBE-RELATED ADVERSE EVENTS IN PLEURAL INFECTION
S123 PREDICTORS OF LONG-TERM POSTOPERATIVE SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA: A MULTIVARIATE ANALYSIS IN 300 PATIENTS TREATED IN A SINGLE INSTITUTION
S124 PNEUMOTHORAX AND PREGNANCY
S125 PLEURECTOMY/DECORTICATION FOR MALIGNANT MESOTHELIOMA
S126 GALACTOMANNAN DETECTION IN EXHALED BREATH CONDENSATE OF NEUTROPENIC PATIENTS WITH SUSPECTED INVASIVE PULMONARY ASPERGILLOSIS
S127 VARIATION IN COLONIAL MORPHOTYPE AND ANTIBIOTIC SUSCEPTIBILITY IN PSEUDOMONAS AERUGINOSA IN SPUTA FROM PATIENTS WITH NON-CYCSTIC FIBROSIS BRONCHIECTASIS AND ITS IMPACT ON ANTIBIOTIC SUSCEPTIBILITY TESTING
S128 LUNG FUNCTION DOES NOT DECLINE IN AN EIGHT-YEAR SURVEILLANCE STUDY OF BRONCHIECTASIS PATIENTS ATTENDING A REGIONAL SPECIALIST CENTRE
S129 COMPLEMENT-MEDIATED IMMUNITY TO STREPTOCOCCUS PNEUMONIAE IS SIGNIFICANTLY IMPAIRED IN SERA FROM PATIENTS WITH HOMOZYGOUS C2 DEFICIENCY
S130 MEASUREMENT OF C-REACTIVE PROTEIN AT DAY 4 CAN DETECT FAILURE OF EMPIRICAL TREATMENT IN COMMUNITY-ACQUIRED PNEUMONIA
S131 DEVELOPMENT OF A NOVEL MURINE MODEL OF PLEURAL EMPYEMA
S132 POTENTIAL ADVANTAGES OF AN INITIAL TELEPHONE CONSULTATION IN THOSE REFERRED FOR A SPECIALIST RESPIRATORY OPINION
S133 AN AUDIT OF PHYSIOTHERAPY AND OCCUPATIONAL THERAPY SERVICES TO MEDICAL PATIENTS IN THE EMERGENCY PORTALS AT UNIVERSITY HOSPITALS OF NORTH STAFFORDSHIRE
S134 BENCHMARKING CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACROSS AN INNER CITY PCT-WIDE POPULATION
S135 THE FIRST SIX MONTHS OF HOSPITAL AND COMMUNITY-BASED OXYGEN ASSESSMENT SERVICE FUNDED BY A PRIMARY CARE TRUST
S136 AN INTEGRATED HOME OXYGEN SERVICE SAVES £130,000 PER YEAR ON HOME OXYGEN TARIFFS
S137 COSTS IMPLICATIONS OF OXYGEN PRESCRIPTION WITHIN A PCT, IF NOT SUPPLIED BY A SPECIALIST RESPIRATORY TEAM
S138 QUADRICEPS MUSCLE ENDURANCE AND ITS RELATION TO PHYSICAL ACTIVITY AND EXERCISE CAPACITY IN COPD
S139 EMPHYSEMA SEVERITY IS ASSOCIATED WITH ARTERIAL STIFFNESS, A MARKER OF CARDIOVASCULAR RISK
S140 PREVALENCE OF ANAEMIA IN STABLE STATE AND DURING EXACERBATION IN A COHORT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS
S141 COPD IS ASSOCIATED WITH ABNORMAL VASCULAR ENDOTHELIAL FUNCTION
S142 SUBCLINICAL BI-VENTRICULAR DYSFUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
S143 CAN SENSEWEAR ACTIVITY MONITORS DETECT SLOW SPEEDS OF WALKING IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE?
S144 ELIGIBILITY FOR AMBULATORY OXYGEN ASSESSMENT CHANGES FOLLOWING A PULMONARY REHABILITATION PROGRAMME
S145 DOES PULMONARY REHABILITATION IN PATIENTS WITH “NON-COPD” CHRONIC RESPIRATORY DISEASE CONFER SIMILAR BENEFITS TO THAT IN PATIENTS WITH COPD?
S146 ASSESSMENT OF PULMONARY REHABILITATION PROGRAMME WITHOUT THE PHYSICAL TRAINING
S147 EARLY OUTCOMES OF A PULMONARY REHABILITATION MAINTENANCE PROGRAMME
S148 BRONCHIAL FIBROBLASTS EXHIBIT A PROINFLAMMATORY RESPONSE TO RHINOVIRUS-16 INFECTION BUT LACK A TYPE I INTERFERON RESPONSE
S149 ALTERED AIRWAY FIBROBLAST COLLAGEN SYNTHESIS IN SEVERE ASTHMA AND THE INVOLVEMENT OF AKT PHOSPHORYLATION
S150 SELDI-TOF MASS SPECTOMETRY SCREENING OF SPUTUM SUPERNATANTS IDENTIFIES NOVEL BIOMARKERS DISTINGUISHING EOSINOPHILIC FROM NON-EOSINOPHILIC ASTHMA
S151 THE ROLE OF GALECTIN-3 IN ASTHMA
S152 INTERSTITIAL AIRWAY WALL FIBROSIS IN ASTHMA AND ITS RELATION TO DISEASE SEVERITY
S153 CROSS SECTIONAL RELATION BETWEEN TOTAL IGE LEVELS, CIGARETTE SMOKING AND FEV 1 IN AN AGEING POPULATION (the ELSA COHORT)
S154 CYCLO-OXYGENASE-2 INDUCTION BY CYCLIC MECHANICAL STRAIN IN HUMAN PRIMARY ALVEOLAR TYPE 2 CELLS AND IN MURINE WHOLE LUNG IS DEPENDENT ON ACTIVATION OF ERK1/2
S155 MARGINATED MONOCYTES EXACERBATE PULMONARY OEDEMA IN A MURINE MODEL OF VENTILATOR-INDUCED LUNG INJURY
S156 PAR1 SIGNALLING IN LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY
S157 THE ROLE OF TNF-RELATED APOPTOSIS INDUCING LIGAND IN ACUTE LUNG INJURY
S158 PLATELETS ARE SEQUESTERED IN THE LUNGS OF EXPERIMENTAL TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI) AND PLATELET DEPLETION PROTECTS MICE FROM TRALI
S159 SALBUTAMOL DRIVES UPREGULATED MMP-9 ACTIVITY IN THE ALVEOLAR SPACE IN ACUTE RESPIRATORY DISTRESS SYNDROME
P1 DEVELOPMENT OF THE BRITISH THORACIC SOCIETY HOME OXYGEN DATABASE AND PREVALENCE OF HOME OXYGEN USE IN ENGLAND AND WALES
P2 DO CURRENT BTS GUIDELINES FOR AIR TRAVEL CORRECTLY IDENTIFY PEOPLE WITH THORACIC SCOLIOSIS WHO BECOME HYPOXAEMIC (PaO 2 <6.6 KPA) ON HYPOXIC CHALLENGE TESTING?
P3 AN AUDIT OF OXYGEN USE IN EMERGENCY AMBULANCES AND IN A HOSPITAL EMERGENCY DEPARTMENT
P4 RESPIRATORY ASSESSMENT CENTRE: A NOVEL WAY TO HANDLE RESPIRATORY EMERGENCIES IN A LARGE TEACHING HOSPITAL
P5 SHOULD ALL CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS WITH CARDIAC COMORBIDITIES HAVE AMBULATORY OXYGEN ASSESSMENT?
P6 AUDIT REVIEWING THE IMPACT OF LUNG ALERT CARDS AND AMBULANCE CREW EDUCATION ON INAPPROPRIATE OXYGEN PRESCRIBING IN PATIENTS WITH COPD
P7 ASSESSMENT FOR AMBULATORY OXYGEN REQUIREMENT IN PATIENTS WITH COPD USING THE 6-MINUTE WALK TEST
P8 APPROPRIATENESS OF EMERGENCY OXYGEN THERAPY FOR COPD PATIENTS
P9 SHORT BURST OXYGEN THERAPY DOES NOT RELIEVE BREATHLESSNESS AFTER EXERCISE IN PATIENTS WITH SEVERE COPD WHO ARE NOT HYPOXAEMIC AT REST
P10 A REVIEW OF THE FIRST YEAR OUTCOMES OF AN OXYGEN ASSESSMENT CLINIC IN A DISTRICT GENERAL HOSPITAL
P11 DOMICILIARY OXYGEN PRESCRIPTION FROM SECONDARY CARE: ARE WE GETTING IT RIGHT?
P12 PREDICTING THE DEVELOPMENT OF HYPERCAPNIA IN PATIENTS UNDERGOING LTOT ASSESSMENT
P13 IS THERE EVIDENCE TO SUPPORT TYPE I RESPIRATORY FAILURE PATIENTS BEING ASSESSED DIFFERENTLY FOR LONG-TERM OXYGEN THERAPY ASSESSMENTS TYPE II FAILURE PATIENTS?
P14 THE NATIONAL LUNG CANCER AUDIT; RESULTS AND PROGRESS FOR THE SECOND YEAR, 2006
P15 IMPROVEMENTS IN MANAGEMENT OF LUNG CANCER PATIENTS FOLLOWING REORGANISATION OF SERVICES AT ST JAMES’S UNIVERSITY HOSPITAL, LEEDS
P16 AN AUDIT OF USE OF CONCURRENT CHEMO-RADIOTHERAPY WITH CISPLATINUM AND VINORELBINE WITH 55 GY IN 20 FRACTIONS IN SEVEN UK TREATMENT CENTRES
P17 ORGANISATION OF LUNG CANCER SERVICES IN MERSEYSIDE AND CHESHIRE: THE LUNG CANCER NURSES’ VIEW
P18 INCIDENCE AND DEMOGRAPHICS OF MESOTHELIOMA ON THE WIRRAL
P19 ABNORMAL RESULTS OF GP-REQUESTED CHEST X RAYS COPIED TO THE HOSPITAL CHEST CLINIC: IS THERE A SIGNIFICANT DELAY BEFORE PATIENTS ARE REFERRED FROM THE COMMUNITY?
P20 A COMPARISON OF CANCER REGISTRY AND HOSPITAL-BASED LUNG CANCER CASE ACQUISITION FOR FOUR HOSPITALS IN WALES IN 2005
P21 REASONS FOR DIAGNOSTIC DELAY IN LUNG CANCER
P22 URGENT 2 WEEK LUNG CANCER REFERRALS FAIL TO IDENTIFY MOST PATIENTS SEEN IN SECONDARY CARE CANCER SERVICE
P23 AUDIT OF LUNG CANCER WAITING TIMES AT A DISTRICT GENERAL HOSPITAL
P24 WHAT HAPPENS TO LUNG CANCER PATIENTS AFTER TREATMENT? AUDIT AT 4 YEARS
P25 GLOBAL PALLIATIVE CARE NEEDS IN LUNG CANCER PATIENTS ARE ASSOCIATED WITH PRESENCE AND SEVERITY OF RESPIRATORY SYMPTOMS BUT NOT INFLAMMATORY RESPONSE OR ALBUMIN LEVEL
P26 STATIN USE REDUCES MARKERS OF SYSTEMIC INFLAMMATION AND 30-DAY MORTALITY IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
P27 DOES DOCUMENTING THE CURB-65 SCORE IMPROVE APPROPRIATE INITIAL EMPIRICAL ANTIBIOTIC THERAPY IN THE MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA?
P28 IS TIMING OF INITIAL ANTIBIOTIC ADMINISTRATION RELATED TO OUTCOME IN COMMUNITY-ACQUIRED PNEUMONIA?
P29 ARE WE PRESCRIBING TOO MANY ANTIBIOTICS FOR ACUTE HOSPITAL ADMISSIONS WITH COMMUNITY ACQUIRED PNEUMONIA?
P30 MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA: APPROPRIATE USE OF SEVERITY ASSESSMENT TOOL
P31 SEVERITY ASSESSMENT AND ADHERENCE TO TREATMENT GUIDELINES HAS POSITIVE IMPACT ON TREATMENT OUTCOME IN HOSPITALISED COMMUNITY-ACQUIRED PNEUMONIA PATIENTS
P32 DO SPIROMETRY, COUGH AND PATIENT PERCEIVED SYMPTOMS CHANGE FOLLOWING INTRAVENOUS ANTIBIOTICS FOR AN ACUTE EXACERBATION OF BRONCHIECTASIS?
P33 OUTCOMES OF EXACERBATIONS OF NON-CYSTIC FIBROSIS BRONCHIECTASIS MANAGED WITH TWO WEEKS’ INTRAVENOUS ANTIBIOTIC THERAPY
P34 MEASUREMENT OF TREM-1 IN EXACERBATIONS OF BRONCHIECTASIS
P35 THE BURDEN OF LUNG DISEASE IN A COHORT OF PATIENTS WITH PRIMARY ANTIBODY DEFICIENCY ON LONG-TERM IMMUNOGLOBULIN REPLACEMENT
P36 EFFICACY OF NEBULISED COLOMYCIN IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS COLONISED WITH PSEUDOMONAS AEURIGONOSA
P37 CYTOMEGALOVIRUS VIRAEMIA AND BRONCHIOLITIS OBLITERANS SYNDROME
P38 SAFETY AND EFFICACY OF INTRAVENOUS COLISTIN IN COMBINATION WITH OTHER ANTIBIOTICS IN LUNG TRANSPLANT RECIPIENTS
P39 CLINICAL PRESENTATION AND COURSE OF HUMAN METAPNEUMOVIRUS IN PAEDIATRIC PATIENTS IN NORTH EAST ENGLAND
P40 SELECTED ION FLOW TUBE MASS SPECTROMETRY BREATH ANALYSIS IN CHILDREN: BAG OR BOX?
P41 MEASURING MARKERS OF OXIDATIVE LUNG INJURY IN CHILDREN USING SELECTED ION FLOW TUBE MASS SPECTROSCOPY
P42 FACTORS INFLUENCING CHANGE IN PEAK EXPIRATORY FLOW DURING CHEST PHYSIOTHERAPY IN MECHANICALLY VENTILATED CHILDREN
P43 A CASE-CONTROL STUDY OF OBSTRUCTIVE SLEEP APNOEA HYPOPNOEA SYNDROME DEMONSTRATED LEFT VENTRICULAR HYPERTROPHY AND LEFT ATRIAL DILATATION IN SUBJECTS WITHOUT KNOWN CARDIAC DISEASE
P44 SLEEP-RELATED DISORDERED BREATHING IN CHILDREN WITH CROUZON SYNDROME
P45 ACHIEVING COMPLIANCE IN THE NON-COMPLIANT PAEDIATRIC PATIENT REQUIRING NOCTURNAL NON-INVASIVE PRESSURE VENTILATION: A FAMILY-CENTRED APPROACH
P46 DOES HYPOXIC CHALLENGE AT SEA LEVEL CORRELATE WITH HYPOXIA IN FLIGHT AND AT ALTITUDE IN HEALTHY CHILDREN?
P47 EFFECT OF THE NICE TUBERCULOSIS GUIDELINES 2006 ON CONTACT TRACING AND NURSING WORKLOAD IN SE LONDON
P48 EVALUATION OF A ROUTINE WHOLE-BLOOD INTERFERON-GAMMA ASSAY IN A HOSPITAL-BASED POPULATION FOR THE DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION
P49 SENSITIVITY, SPECIFICITY AND JUSTIFICATION OF THE T-SPOT TB ASSAY CUT-OFF USING RECEIVED OPERATOR CHARACTERISTIC (ROC) ANALYSIS
P50 A COMPARISON OF INTERFERON-GAMMA RELEASE ASSAYS AND DIAGNOSTIC ALGORITHMS FOR LATENT TUBERCULOSIS
P51 THE DIAGNOSTIC EFFICACY OF FINE NEEDLE ASPIRATION UTILISING CYTOLOGY AND TB CULTURE IN TUBERCULOUS LYMPHADENITIS
P52 SPINAL TUBERCULOSIS: A DIAGNOSIS NOT TO BE MISSED—A REVIEW OF CASES
P53 CONTACT TRACING IN AN HIV POSITIVE POPULATION: A COMBINED APPROACH USING MANTOUX, GAMMA INTERFERON ASSAY (T-SPOT TB), CHEST x ray and symptom questionnaire
P54 NEW ENTRANT SCREENING STRATEGIES FOR TUBERCULOSIS: A WORTHWHILE CAUSE?
P55 NURSE LED RAPID ACCESS CLINIC REDUCES WAITING TIMES AND ENSURES TIMELY AND EFFECTIVE DIAGNOSIS AND MANAGEMENT OF TUBERCULOSIS
P56 DO TRADITIONAL HEALERS INFLUENCE THE MANAGEMENT OF TUBERCULOSIS PATIENTS? TREATMENT DELAY AND PATIENT CONSULTATION PATTERNS IN RURAL ZIMBABWE
P57 INFECTION AFFECTS ENDOTHELIUM-DEPENDENT PULMONARY VASCULAR RESPONSES IN REJECTING SINGLE LUNG TRANSPLANTS
P58 VENTRICULAR MASS INDEX MEASURED USING MAGNETIC RESONANCE IMAGING CORRELATES WITH PULMONARY ARTERY PRESSURE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND SUSPECTED PULMONARY ARTERIAL HYPERTENSION
P59 THE NATRIURETIC RESPONSE ON ACUTE ASCENT TO HIGH ALTITUDE
P60 COMPARING 6 MINUTE WALK AND HYPOXIC CHALLENGE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
P61 REDUCED INCREMENTAL SHUTTLE WALKING TEST DISTANCE IS ASSOCIATED WITH A WORSE SURVIVAL IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS
P62 THE PHYSIOFLOW 1 THORACIC BIOIMEPEDANCE DEVICE FOLLOWS TRENDS IN CARDIAC OUTPUT CHANGES IN PATIENTS WITH PULMONARY HYPERTENSION
P63 ELEVATIONS OF PROTHROMBOTIC FACTOR VIII IN HEREDITARY HAEMORRHAGIC TELANGIECTASIA: ASSOCIATION WITH AGE AND PULMONARY ARTERIOVENOUS MALFORMATIONS, BUT NOT PULMONARY ARTERY PRESSURE
P64 DIFFERENTIAL TREATMENT REFERRAL RATES FOR PULMONARY ARTERIOVENOUS MALFORMATION PATIENTS, ACCORDING TO MEDICAL RECOGNITION OF NEUROLOGICAL RISK
P65 MATERNAL DEATH DURING PREGNANCY: SURVIVAL ADVANTAGE FOR WOMEN WITH PRE-EXISTING DIAGNOSES OF PULMONARY ARTERIOVENOUS MALFORMATIONS OR HEREDITARY HAEMORRHAGIC TELANGIECTASIA
P66 MASS SPECTROMETRY: A NON-INVASIVE MEASURE OF PULMONARY BLOOD FLOW IN PATIENTS WITH PULMONARY HYPERTENSION
P67 AIRWAY CLEARANCE IN BRONCHIECTASIS: IS NON-INVASIVE VENTILATION A USEFUL ADJUNCT IN MODERATE TO SEVERE DISEASE
P68 A BENCH TEST TO ESTABLISH THE CORE PRINCIPLES OF ADAPTIVE SERVOVENTILATION
P69 DOES WEIGHT LOSS PREDICT CESSATION OF NON-INVASIVE VENTILATION FOR OBESITY RELATED HYPOVENTILATION?
P70 NON-INVASIVE VENTILATION AS CEILING OF TREATMENT IN ACUTE EXACERBATION OF COPD: IS THERE A RELATIONSHIP BETWEEN STARTING PH AND MORTALITY?
P71 INTUBATION RATE, MORTALITY AND BLOOD GAS OUTCOMES IN EXACERBATION OF COPD PRESENTING WITH HYPERCAPNIC RESPIRATORY ACIDOSIS TREATED BY NIV: A 3 YEAR SURVEY
P72 SURVEY OF KNOWLEDGE OF HEALTH CARE PROFESSIONALS MANAGING PATIENTS WITH ACUTE HYPERCAPNIC EXACERBATION OF COPD REQUIRING NON-INVASIVE VENTILATION
P73 INITIATION OF NON-INVASIVE VENTILATION IN THE EMERGENCY DEPARTMENT DURING ACUTE EXACERBATION OF COPD MAY INFLUENCE HOSPITAL MORTALITY
P74 OXYGEN THERAPY BEFORE INITIATION OF NON-INVASIVE VENTILATION IN COPD PATIENTS PRESENTING WITH RESPIRATORY FAILURE
P75 AN EXPLORATORY STUDY OF PSYCHOSOCIAL FACTORS IN THE PROCESS OF WEANING FROM MECHANICAL VENTILATION
P76 THE USE OF A NON-INVASIVE VENTILATION (NIV) PROFORMA IMPROVES SUCCESSFUL WEANING FROM NIV ON A RESPIRATORY WARD
P77 USING A PROTOCOL REDUCES WEANING TIME IN NON-INVASIVE VENTILATION PATIENTS MANAGED ON MEDICAL WARDS
P78 USE OF THE DIAPHRAGM ELECTROMYOGRAM TO ASSESS THE RESPONSE TO BRONCHODILATOR THERAPY IN ASTHMA AND COPD
P79 EXPIRATORY MUSCLE AND COUGH FUNCTION AFTER ACUTE ISCHAEMIC STROKE
P80 MULTI-DIMENSIONAL ASSESSMENT OF CLINICAL DYSPNOEA
P81 USE OF THE ECCS REFERENCE EQUATIONS IN THE INTERPRETATION OF LUNG FUNCTION TESTS: TIME TO CHANGE?
P82 DIMENSIONS OF BREATHLESSNESS AT REST AND ON EXERTION IN RESPIRATORY DISEASE
P83 ADJUSTMENT OF DIFFUSING CAPACITY FOR CARBON MONOXIDE (DLCO) FOR HAEMOGLOBIN VALUE IN UK LABORATORIES
P84 HYPERINFLATION IN HEALTHY ADULTS INDUCED BY BREATHING AGAINST A CONSTANT RESPIRATORY LOAD
P85 IS PACED BREATHING IMPORTANT WHEN APPLYING A CONSTANT RESISTANCE TEST?
P86 MEASURING CARBON MONOXIDE TRANSFER HELPS TO UNDERSTAND THE PATHOPHYSIOLOGY OF LUNG DISEASE IN PATIENTS WITH SICKLE CELL ANAEMIA
P87 PREDNISOLONE PHARMACOKINETICS IN SEVERE ASTHMATICS: DELAYED ABSORPTION AND FAILURE TO SUPPRESS ENDOGENOUS CORTISOL
P88 USAGE OF A NEW ELECTRONIC ASTHMA ACTION PLAN IN PRIMARY CARE
P89 REAL LIFE EFFECTIVENESS IN ASTHMA OF SYMBICORT MAINTENANCE AND RELIEVER THERAPY: RESULTS OF THE RELEASE STUDY
P90 THE EFFECTIVENESS OF A DIFFICULT ASTHMA SERVICE FROM THE PATIENT’S PERSPECTIVE
P91 A UK SURVEY OF ORAL CORTICOSTEROID USE IN PATIENTS TREATED WITH OMALIZUMAB
P92 TREATMENT AND FOLLOW-UP OF ACUTE SEVERE ASTHMA: WHO DOES IT BEST?
P93 SEASONAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS
P94 DEVELOPMENT OF AN ALGORITHM FOR THE ASSESSMENT OF RESPONSE TO TREATMENT WITH OMALIZUMAB
P95 IS IT IMPORTANT THAT RESPIRATORY PHYSICIANS REVIEW ALL GP REFERRAL LETTERS?
P96 UNDERSTANDING OF DISEASE IN PATIENTS NEWLY DIAGNOSED WITH TUBERCULOSIS IN EAST LONDON
P97 DEVELOPMENT OF A MULTIMEDIA RESPIRATORY RESOURCE TOOL FOR USE IN PRIMARY CARE
P98 TRAINING ABROAD: IS IT THE END?
P99 COMPREHENSION OF PICTORIAL ASTHMA ACTION PLANS BY SOMALIS AND MALAYSIANS
P100 INTERCOSTAL DRAIN INSERTION: A SURVEY OF GENERAL MEDICAL REGISTRARS IN THE MID TRENT REGION
P101 A COMPARISON OF JUNIOR TRAINEES’ KNOWLEDGE OF NON-INVASIVE VENTILATION VERSUS THROMBOLYSIS
P102 ELASTASE INHIBITOR DX-890 PREVENTS IL-8 RELEASE STIMULATED BY NEUTROPHIL ELASTASE BUT NOT IL-8 RELEASE STIMULATED BY CYSTIC FIBROSIS SPUTUM
P103 COMPARISON OF THE ORAL GLUCOSE TOLERANCE TEST AND SERIAL GLUCOSE MONITORING IN CYSTIC FIBROSIS PATIENTS
P104 MANAGEMENT OF CYSTIC FIBROSIS RELATED DIABETES IN THE UK
P105 AN AUDIT OF PROPHYLACTIC ANTI-PSEUDOMONAL ANTIBIOTIC USE IN AN ADULT CYSTIC FIBROSIS CLINIC
P106 REGIONAL IMPROVEMENTS IN PAEDIATRIC CYSTIC FIBROSIS OUTCOMES FOR THE YEARS 1992, 1998 AND 2005
P107 EFFECTS OF LUNG FUNCTION AND EXERCISE CAPACITY ON QUALITY OF LIFE IN CYSTIC FIBROSIS USING THE UK CYSTIC FIBROSIS QUESTIONNAIRE
P108 SELF-REPORTED FATIGUE AND QUALITY OF LIFE IN ADULT PATIENTS WITH CYSTIC FIBROSIS
P109 PROVISION OF CONTRACEPTION AND SEXUAL HEALTH SERVICES FOR WOMEN WITH CYSTIC FIBROSIS
P110 SWEAT CHLORIDE CONCENTRATIONS AND CFTR GENE MUTATIONS IN LATE DIAGNOSED CYSTIC FIBROSIS
P111 ASSESSING ULTRASOUND AS A METHOD TO ENHANCE NON-VIRAL GENE TRANSFER TO THE LUNG
P112 BACTOFECTION INTO AIRWAY EPITHELIAL CELLS IN VITRO AND IN VIVO USING A GENETICALLY MODIFIED ESCHERICHIA COLI
P113 A FOLLOW-UP STUDY OF PATIENTS WHO HAVE HAD LAPAROSCOPIC FUNDOPLICATION AS A TREATMENT FOR THEIR COUGH
P114 LARYNGEAL APPEARANCES AND PROXIMAL REFLUX IN CHRONIC COUGH
P115 HOW TO QUANTIFY COUGHING? CORRELATIONS WITH QUALITY OF LIFE IN PATIENTS WITH CHRONIC COUGH
P116 NOCTURNAL AND POST-PRANDIAL COUGH FREQUENCIES AMONG PATIENTS WITH DIFFERENT CAUSES OF CHRONIC COUGH
P117 DIAGNOSIS AND SUCCESSFUL MANAGEMENT OF PERSISTENT COUGH IN A DEDICATED COUGH CLINIC: A DISTRICT GENERAL HOSPITAL EXPERIENCE
P118 CLINICAL FEATURES OF IDIOPATHIC CHRONIC COUGH
P119 INTER- AND INTRA-OBSERVER VARIABILITY OF MANUAL COUGH COUNTING IN COUGH CHALLENGE TESTING
P120 ANXIETY, DEPRESSION AND QUALITY OF LIFE MEASURES IN PATIENTS WITH CHRONIC PERSISTENT COUGH
P121 THE EFFECT OF AMILORIDE ON CITRIC ACID INDUCED COUGH
P122 THE EFFECTS OF VOLUNTARY COUGHING ON THE AIRWAYS IN MILD ASTHMA
P123 PREVALENCE OF OBSTRUCTIVE SLEEP APNOEA IN A POPULATION OF MORBIDLY OBESE PATIENTS REFERRED FOR BARIATRIC SURGERY AND POSTOPERATIVE OUTCOMES
P124 AN EVALUATION OF THE “DYNAMAX” MANDIBULAR APPLIANCE IN OBSTRUCTIVE SLEEP APNOEA IN A DISTRICT GENERAL HOSPITAL
P125 OVERTONE SINGING: A TREATMENT FOR SNORING AND OBSTRUCTIVE SLEEP APNOEA?
P126 COMPARING PRIMARY AND SECONDARY CARE REFERRALS TO A SLEEP APNOEA CLINIC
P127 COMPLIANCE WITH CONTINUOUS POSITIVE AIRWAY PRESSURE THERAPY IN TYPE 2 LICENCE HOLDERS WITH MODERATE TO SEVERE SLEEP APNOEA
P128 SHOULD WE SELECT PATIENTS FOR CONTINUOUS POSITIVE AIRWAY PRESSURE TRIALS BY OVERNIGHT OXIMETRY OR EPWORTH SCORE?
P129 CAN PATIENTS SELF-ADMINISTER THE EPWORTH SLEEPINESS SCALE?
P130 BASELINE BLOOD PRESSURE AND HYPERSOMNOLENCE PREDICT BP FALL WITH CPAP TREATMENT OF OSA
P131 ENDOTHELIAL PROGENITOR CELL NUMBER: A NOVEL CONCEPT IN PATHOGENESIS OF INCREASED CARDIOVASCULAR RISKS IN OBSTRUCTIVE SLEEP APNOEA SYNDROME
P132 CHANGES IN CEREBRAL BLOOD FLOW DURING OF AROUSAL FROM SLEEP IN HEALTHY HUMANS
P133 PREDICTING CONTINUOUS POSITIVE AIRWAY PRESSURE STARTING PRESSURES IN PATIENTS WITH OBSTRUCTIVE SLEEP APNOEA
P134 CORRELATION OF ALVEOLAR MORPHOLOGY AND PULMONARY FUNCTION IN THE DEXAMETHASONE-TREATED MOUSE MODEL OF EMPHYSEMA
P135 ROLE OF THE EPITHELIAL GROWTH FACTOR RECEPTOR IN MEDIATING PROINFLAMMATORY RESPONSES TO RESIDUAL OIL FLY ASH
P136 ABERRANT LOCAL STEROID METABOLISM AND ITS MODULATION BY INTRAVENOUS SALBUTAMOL IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME
P137 LIPOPOLYSACCHARIDE-INDUCED UPREGULATION OF TUMOUR NECROSIS FACTOR-ALPHA CONVERTING ENZYME ACTIVITY ON PRIMARY HUMAN MONOCYTES
P138 SUBVERSION OF NEUTROPHIL APOPTOSIS BY STAPHYLOCOCCUS AUREUS
P139 A FAMILY WITH A NOVEL CHROMOSOMAL REARRANGEMENT: A RESOURCE TO IDENTIFY A FURTHER GENE FOR PULMONARY ARTERIOVENOUS MALFORMATIONS AND HEREDITARY HAEMORRHAGIC TELANGIECTASIA
P140 THE ALK3/BMPR-II RECEPTOR COMPLEX MEDIATES BMP-DEPENDENT SMAD1/5 PHOSPHORYLATION IN HUMAN PULMONARY ARTERY SMOOTH MUSCLE CELLS
P141 EPIGENETIC MECHANISMS SILENCE ADAM33 EXPRESSION IN BRONCHIAL EPITHELIAL CELLS
P142 A POLYMORPHISM IN THE MATRIX METALLOPROTEINASE 9 GENE MAY INFLUENCE EMPHYSEMA DISTRIBUTION IN ALPHA 1 ANTI-TRYPSIN DEFICIENCY
P143 LUNG AND BLOOD T CELL DIFFERENTIATION IN UNTREATED TUBERCULOSIS
P144 USING TRANSGENIC ZEBRAFISH MODELS TO HELP UNDERSTAND INFLAMMATORY LUNG DISEASE
P145 FATIGUE AT EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P146 CHARACTERISTICS OF PATIENTS WHO HAVE A FIRST ADMISSION WITH AN ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P147 RISK FACTORS FOR PROLONGED ADMISSION AND EARLY READMISSION IN COPD: A PILOT STUDY USING PARR SCORE
P148 IS EXACERBATION FREQUENCY RELATED TO SOCIAL FACTORS?
P149 SEVERITY CLASSIFICATION OF EXACERBATIONS BASED ON QUANTIFICATION FROM DIARY CARD SYMPTOM LENGTHS AND SCORES
P150 DO FREQUENT EXACERBATORS WITH COPD PERCEIVE THEIR EXACERBATION FREQUENCY MORE ACCURATELY THAN INFREQUENT EXACERBATORS?
P151 REPORTED AND UNREPORTED EXACERBATIONS OF COPD-ANALYSIS BY DIARY CARDS
P152 MANAGEMENT OF COPD EXACERBATIONS IN THE WEEK BEFORE HOSPITAL ADMISSION
P153 QUALITY INDICATORS FOR NON-INVASIVE VENTILATION SERVICES: A SURVEY OF 100 UK NHS HOSPITALS
P154 SURVEY OF THE USE OF NON-INVASIVE VENTILATION IN THE CLINICAL MANAGEMENT OF ACUTE COPD IN 233 UK HOSPITALS
P155 DOES MANAGEMENT OF ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE COMMUNITY IMPROVE THE OUTCOMES? A PROSPECTIVE OBSERVATION STUDY
P156 A PILOT STUDY OF INTENSIVE PHYSIOTHERAPY AND RESPIRATORY NURSING INPUT FOR PATIENTS WITH AECOPD ADMITTED TO GENERAL MEDICAL WARDS
P157 CAUSE OF DEATH IN PATIENTS HOSPITALISED WITH ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P158 SURVEY OF A MULTIDISCIPLINARY MEETING FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE
P159 COHORT MORTALITY STUDY OF CRYPTOGENIC FIBROSING ALVEOLITIS
P160 THE PROGNOSTIC VALUE OF HIGH RESOLUTION CT SCORES IN PATIENTS WITH CRYPTOGENIC FIBROSING ALVEOLITIS SYNDROME AND A CLINICO-RADIOLOGICAL DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS/FIBROTIC NON-SPECIFIC INTERSTITIAL PNEUMONIA
P161 RELATIONSHIP BETWEEN RIGHT HEART CATHETERISATION AND NON-INVASIVE MEASURES OF PULMONARY HYPERTENSION IN PATIENTS WITH FIBROSING LUNG DISEASE
P162 ESTIMATION OF ASBESTOS FIBRE CONCENTRATION IN INDUSTRIES CONSISTENT WITH RISK OF ASBESTOS-RELATED DISEASE
P163 LUNG TRANSPLANT REFERRALS FOR IDIOPATHIC PULMONARY FIBROSIS IN NOTTINGHAM
P164 IS HIGH RESOLUTION CT USEFUL FOR PREDICTING LUNG FUNCTION DECLINE IN PULMONARY SARCOIDOSIS? A RETROSPECTIVE STUDY OF 21 CASES
P165 FAMILIAL IDIOPATHIC PULMONARY FIBROSIS, WITH BONE MARROW HYPOPLASIA AND HEPATIC NODULAR REGENERATIVE HYPERPLASIA: A NEW SYNDROME?
P166 DIAGNOSTIC YIELD OF THE CLINICAL INVESTIGATIONS OF PLEURAL EFFUSION
P167 CLOSED PLEURAL BIOPSY IN DIAGNOSIS OF SUSPECTED PLEURAL MALIGNANCY: HOW USEFUL IS IT?
P168 SPECIALIST REGISTRAR LED CHEST ULTRASOUND SERVICE IN A LARGE TEACHING HOSPITAL
P169 AN AUDIT OF PERCUTANEOUS PLEURAL BIOPSY IN THE INVESTIGATION OF PLEURAL EFFUSION IN A DISTRICT GENERAL HOSPITAL
P170 THE USE OF BEDSIDE THORACIC ULTRASONOGRAPHY IN A DISTRICT GENERAL HOSPITAL
P171 PROPHYLACTIC ANTIBIOTICS FOR MEDICAL THORACOSCOPY: IS THERE A NEED FOR IT?
P172 COMPLIANCE WITH BRITISH THORACIC SOCIETY GUIDELINES FOR THE MANAGEMENT OF SPONTANEOUS PNEUMOTHORAX IN 2 UK TEACHING HOSPITALS
P173 THE MANAGEMENT OF SPONTANEOUS PNEUMOTHORAX
P174 ARE WE CONFORMING TO CURRENT BTS GUIDELINES ON THE MANAGEMENT OF PRIMARY SPONTANEOUS PNEUMOTHORAX?
P175 IS SURGICAL ACCESS OR PROCEDURE PERFORMED THE PRINCIPAL DETERMINANT OF OUTCOME FOR SURGERY TO PREVENT RECURRENT PNEUMOTHORACES?
P176 CASE SERIES OF ATYPICAL PRESENTATION OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
P177 RELATIONSHIP BETWEEN ASTHMA SYMPTOMS, SPIROMETRY, DISEASE SEVERITY AND EXHALED NITRIC OXIDE WITH EXACERBATION RATE IN PATIENTS ATTENDING ROUTINE PRIMARY CARE NURSE-LED CLINICS
P178 THE CORRELATION BETWEEN EXHALED NITRIC OXIDE AND SPUTUM EOSINOPHIL COUNTS IN PATIENTS WITH AIRWAYS DISEASE
P179 A STUDY OF AIRWAY INFLAMMATION AND VIRAL INFECTION IN ACUTE SEVERE ASTHMA
P180 EXHALED NO (FE NO ) CORRELATES TO SPUTUM EOSINOPHIL COUNT IN ACUTE SEVERE ASTHMA
P181 ATOPY AND SARCOIDOSIS: A PILOT STUDY SHOWING CORRELATION WITH DISEASE STAGE
P182 TNF-ALPHA ANTAGONISM USING ETANERCEPT REDUCES SYSTEMIC INFLAMMATION AND SPUTUM MACROPHAGES IN SEVERE ASTHMA
P183 THE PAPER RECYCLING INDUSTRY, HYDROXYLAMINE AND OCCUPATIONAL ASTHMA: TWO CASE REPORTS
P184 THE OUTCOME OF OCCUPATIONAL ASTHMA WITH CONTINUING EXPOSURE: A SYSTEMATIC REVIEW
P185 THE EFFECT OF WELDING ON LUNG FUNCTION DECLINE AND RESPIRATORY SYMPTOMS: A SYSTEMATIC REVIEW
P186 ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN THE UK
P187 SPUTUM GRANULOCYTE CELL TYPE DOES NOT PREDICT RATE OF RECOVERY OF PEAK EXPIRATORY FLOW IN ACUTE SEVERE ASTHMA
P188 ANTHRACOFIBROSIS: A MIMIC OF LUNG CANCER. IS IT THE PMF OF THE AIRWAYS?
P189 OUTCOME FOR PATIENTS WITH NEGATIVE FDG-PET SCANS
P190 PROGNOSTIC FACTORS FOR LONG-TERM SURVIVAL AFTER PULMONARY METASTASECTOMY IN SARCOMA PATIENTS: A 12 YEAR EXPERIENCE
P191 PROGNOSTIC IMPLICATIONS OF IMPROVED CT DETECTION OF PULMONARY METASTASES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY
P192 FOLLOW-UP OF ISOLATED PULMONARY NODULES DISCOVERED BY CT SCAN
P193 PREOPERATIVE FEV 1 <2 L DOES NOT ACCURATELY PREDICT THE DEVELOPMENT OF COMPLICATIONS FOLLOWING A PNEUMONECTOMY
P194 DOES THE USE OF BRONCHOSCOPY IN THE INVESTIGATION OF HAEMOPTYSIS IMPROVE THE DIAGNOSIS OF EARLY LUNG CANCER?
P195 LUNG CANCER BRONCHOSCOPY WITH NO VISIBLE TUMOUR: IMPACT OF TRANSBRONCHIAL NEEDLE ASPIRATION
P196 COMPARATIVE YIELD OF TRANSBRONCHIAL NEEDLE ASPIRATION (CONVENTIONAL AND ENDOBRONCHIAL ULTRASOUND GUIDED) AND PET-CT IN THE EVALUATION OF MEDIASTINAL malignancy
P197 INTERVENTIONAL FLEXIBLE BRONCHOSCOPY: WHAT TO EXPECT FROM A NEW SERVICE
P198 A PROSPECTIVE AUDIT EXAMINING THE IMPACT OF INTEGRATED PET-CT SCANNING ON LUNG CANCER MULTIDISCIPLINARY TEAM DECISION MAKING
P199 PULMONARY MALIGNANCY IN PATIENTS WITH A PREVIOUS DIAGNOSIS OF BREAST CANCER
P200 PRESENTING SYMPTOMS, CHEST RADIOGRAPH ABNORMALITIES AND FEV 1 IN GP REFERRALS FOR SUSPECTED LUNG CANCER: HOW WELL DO THEY DISCRIMINATE?
P201 MEASUREMENT OF OPEN CAPACITY IN STABLE COPD PATIENTS
P202 AN OBSERVATIONAL STUDY OF THE PREVALENCE OF ANAEMIA IN MODERATE TO SEVERE COPD
P203 ULTRASOUND MEASUREMENT OF RECTUS FEMORIS MUSCLE CROSS-SECTIONAL AREA AND THE RELATIONSHIP WITH WHOLE BODY FAT FREE MASS AND QUADRICEPS STRENGTH IN COPD
P204 MUSCLE RING FINGER PROTEIN 1 (MURF-1), ATROGIN-1 AND MUSCLE WASTING IN COPD
P205 THE EFFECT OF MUSCLE WASTING ON EXERCISE CAPACITY AND DEPRESSION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P206 ELEVATED C REACTIVE PROTEIN LEVELS ARE ASSOCIATED WITH AN ACCELERATED DECLINE IN LUNG FUNCTION IN AN AGEING POPULATION
P207 TEN YEAR LONGITUDINAL CHANGE IN LUNG FUNCTION AND C REACTIVE PROTEIN IN MIDDLE-AGED MEN IN NORTHERN IRELAND
P208 STABILITY OF AIRWAY AND SYSTEMIC INFLAMMATORY BIOMARKERS IN MODERATE COPD PATIENTS OVER 1 YEAR
P209 CT ASSESSMENT OF COPD PHENOTYPE IN A COHORT OF 133 PATIENTS
P210 WHEN SHOULD WE START MONITORING ALPHA-1 ANTITRYPSIN DEFICIENT SUBJECTS?
P211 USE OF THE OESOPHAGEAL DIAPHRAGM ELECTROMYOGRAM TO DETERMINE NEURAL RESPIRATORY DRIVE IN HEALTHY SUBJECTS AND IN COPD
P212 MEASURING HAT:HDAC ACTIVITY RATIO IN SPUTUM MACROPHAGES: A NON-INVASIVE METHOD FOR DETECTING INFLAMMATORY STATUS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P213 AORTIC CALCIFICATION IS DIRECTLY RELATED TO ARTERIAL STIFFNESS AND INVERSELY RELATED TO BONE MINERAL DENSITY IN PATIENTS WITH COPD
P214 ARTERIAL STIFFNESS IS REDUCED BY COMBINATION INHALED CORTICOSTEROID/LONG ACTING BETA-2 AGONIST THERAPY IN PATIENTS WITH COPD
P215 SURVEY OF THE PRESCRIPTION OF VENOUS THROMBOPROPHYLAXIS PRESCRIPTION IN MEDICAL INPATIENTS
P216 CLINICAL SETTINGS AND PATIENT FACTORS SIGNIFICANTLY INFLUENCE DIAGNOSTIC UTILITY OF D-DIMER IN VENOUS THROMBOEMBOLISM
P217 CLINICAL PROBABILITY ASSESSMENT AND D-DIMER ASSAY USE IN PATIENTS UNDERGOING CT PULMONARY ANGIOGRAM FOR SUSPECTED ACUTE PULMONARY EMBOLISM
P218 USE OF CT PULMONARY ANGIOGRAPHY AS THE FIRST LINE IMAGING MODALITY FOR PULMONARY EMBOLISM IN A MEDIUM-SIZED DISTRICT HOSPITAL
P219 CT SCAN RADIATION CAN EQUAL ATOMIC BOMB EXPOSURE: AN AUDIT TO INVESTIGATE THE APPROPRIATE USE OF CT PULMONARY ANGIOGRAPHY IN INVESTIGATION OF SUSPECTED PULMONARY EMBOLISM
P220 AN AUDIT OF CT PULMONARY ANGIOGRAM REFERRALS IN THE DIAGNOSIS OF ACUTE PULMONARY EMBOLISM: IS THERE ADHERENCE TO NATIONAL GUIDELINES?
P221 HIGH PREVALENCE OF MULTIPLE RISK FACTORS FOR VENOUS THROMBOEMBOLISM AMONG HOSPITALISED MEDICAL PATIENTS: A CASE FOR MANDATORY FRONT-OF-HOUSE PRIMARY THROMBOPROPHYLAXIS FOR ALL MEDICAL ADMISSIONS
P222 A REVIEW OF PATIENTS ADMITTED WITH PULMONARY EMBOLISM TO DETERMINE HOW MANY CAN BE MANAGED SAFELY AS OUTPATIENTS
P223 PULMONARY REHABILITATION IN NORTHERN IRELAND: A REGIONAL SURVEY
P224 A SURVEY OF PULMONARY REHABILITATION SERVICES PROVIDED IN ENGLAND IN JUNE 2007 COMPARED TO 2002
P225 THE IMPACT OF THE 2004 NICE GUIDELINE AND 2003 GENERAL MEDICAL SERVICES CONTRACT ON COPD IN PRIMARY CARE IN THE UK
P226 GUIDELINE ADHERENCE WHEN TREATING COPD IN UK PRIMARY CARE
P227 ARE INHALED CORTICOSTEROIDS BEING PRESCRIBED APPROPRIATELY IN COPD?
P228 DOCTORS’ ACTION AND ATTITUDE TO CURRENT SMOKERS LIMITED BY COPD OR ANGINA, COMPARED WITH PATIENTS LIMITED BY ALCOHOL OR DRUG ABUSE
P229 COMPARATIVE ASSESSMENT OF CONTINUOUS TREATMENT FOR DIAGNOSED COPD WITH TIOTROPIUM BROMIDE (TIOTROPIUM®), COMBINED IPRATROPIUM AND SALBUTAMOL (COMBIVENT®): A 12-MONTH FOLLOW-UP STUDY IN THE GENERAL PRACTICE RESEARCH DATABASE (GPRD)
P230 END OF LIFE PLANNING FOR SEVERE COPD: A PILOT STUDY
P231 DETERMINANTS OF FATIGUE IN STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P232 CLINICAL FEATURES USED BY HOSPITAL PHYSICIANS TO DIAGNOSE COPD AND CONCORDANCE WITH ACCEPTED DIAGNOSTIC CRITERIA
P233 AN INTEGRATED RESPIRATORY TEAM SPANNING PRIMARY AND SECONDARY CARE CAN REDUCE HOSPITAL ADMISSIONS AND GP CONSULTATIONS FOR COPD
P234 REMOTE DAILY REAL TIME MONITORING OF SYMPTOMS IN PATIENTS WITH COPD: MOBILE TECHNOLOGY AND EXACERBATIONS (MOTEX) STUDY
P235 DEPRESSION AND COPD